Related Experiment Video

Updated: Oct 5, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells

M E Lane1, B Yu, A Rice

  • 1Division of Oncology, Department of Medicine, Albert Einstein College of Medicine and the Albert Einstein Cancer Center, Bronx, New York 10461, USA.

Cancer Research
|August 17, 2001
PubMed

Insights

The novel compound SU9516 selectively inhibits cyclin-dependent kinase 2 (cdk2), a key target for cancer drugs. This inhibition disrupts cell cycle progression, offering a promising strategy for developing new antineoplastic agents.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Oncology

Background:

  • Cyclin-dependent kinase (cdk)2 inhibitors targeting E2F deregulation are a potential strategy for novel antineoplastic agents.
  • Selective inhibition of cdk2 is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To investigate the inhibitory effects of SU9516 on cdk2 activity.
  • To evaluate the downstream effects of SU9516-induced cdk2 inhibition on retinoblastoma protein (pRb) phosphorylation, caspase-3 activation, and cell cycle progression.
  • To explore potential cell line variations in cdk-dependent pRb phosphorylation.

Main Methods:

  • Biochemical assays to determine SU9516 binding and selective inhibition of cdk2.
  • Western blotting to assess pRb phosphorylation levels.
  • Caspase-3 activity assays.
  • Flow cytometry to analyze cell cycle distribution.

Main Results:

  • SU9516 selectively binds to and inhibits cdk2 activity.
  • Inhibition of cdk2 by SU9516 leads to decreased pRb phosphorylation (4-64%) and increased caspase-3 activation (5-84%).
  • SU9516 induces cell cycle arrest at either the G(0)-G(1) or G(2)-M phase, with observed cell line-specific differences in pRb phosphorylation.

Conclusions:

  • SU9516 is a potent and selective cdk2 inhibitor.
  • These findings support the therapeutic potential of cdk2 inhibitors in cancer treatment.
  • SU9516 represents a viable resource for the development of new antineoplastic agents.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...